Key result
The Enhanced Recovery After Surgery (ERAS) pathway significantly reduced the length of hospital stay for endometrial cancer patients compared to non-ERAS care (3.18 vs. 4.87 days, p < 0.0001).
Why the study?
The impact of Enhanced Recovery After Surgery (ERAS) protocols on endometrial cancer management has not been well-established.
Does the ERAS pathway reduce length of hospital stay in endometrial cancer patients?
Observational (n=427)
No
Does the ERAS pathway reduce length of hospital stay in endometrial cancer patients?
ERAS protocols significantly reduce length of hospital stay and increase early discharge rates in endometrial cancer patients, particularly those over 70 years old, without increasing post-operative complications.
Answers are grounded in this paper and cite their sources.
ERAS may shorten hospital stay after endometrial cancer surgery; leaves open confirmation in randomized trials before practice change.
Endometrial cancer is the fifth most common cancer among French women and occurs most frequently in the over-70-year-old population. Recent years have seen a significant shift towards minimally invasive surgery and Enhanced Recovery After Surgery (ERAS) protocols in endometrial cancer management. However, the impact of ERAS on endometrial cancer has not been well-established. We conducted a prospective observational study in a comprehensive cancer center, comparing the outcomes between endometrial cancer patients who received care in an ERAS pathway (261) and those who did not (166) between 2006 and 2020. We performed univariate and multivariate analysis. Our primary objective was to evaluate the impact of ERAS on length of hospital stay (LOS), with the secondary objectives being the determination of the rates of early discharge, post-operative morbidity, and rehospitalization. We found that patients in the ERAS group had a significantly shorter length of stay, with an average of 3.18 days compared to 4.87 days for the non-ERAS group (estimated decrease −1.69, p < 0.0001). This effect was particularly pronounced among patients over 70 years old (estimated decrease −2.06, p < 0.0001). The patients in the ERAS group also had a higher chance of early discharge (47.5% vs. 14.5% in the non-ERAS group, p < 0.0001), for which there was not a significant increase in post-operative complications. Our study suggests that ERAS protocols are beneficial for the management of endometrial cancer, particularly for older patients, and could lead to the development of ambulatory pathways.
No takes yet. Share an insight, caveat, or question.
Miguet et al. (2023) conducted an observational in Endometrial cancer (n=427). Enhanced Recovery After Surgery (ERAS) pathway vs. Non-ERAS pathway was evaluated on Length of hospital stay (LOS) (estimated decrease -1.69, p=< 0.0001). The Enhanced Recovery After Surgery (ERAS) pathway significantly reduced the length of hospital stay for endometrial cancer patients compared to non-ERAS care (3.18 vs. 4.87 days, p < 0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: